Boston Scientific

Latest Headlines

Latest Headlines

Boston Scientific dealt $73M blow in vaginal mesh case

Boston Scientific was dealt a crushing blow in its vaginal mesh saga, as a Texas state jury ordered the devicemaker to pay $73 million to a woman who claimed chronic pain and injury from the company's vaginal mesh implant.

Boston Scientific faces stinging setback for vagus nerve stimulation device in mid-stage trial

Boston Scientific is facing a stinging setback in the highly competitive neuromodulation field as the company's vagus nerve stimulation (VNS) device failed to improve cardiac function in a recent mid-stage clinical trial.

Boston Sci gets bad news on four of 23,000+ vaginal mesh lawsuits

Boston Scientific faces more than 23,000 lawsuits over its Pinnacle transvaginal mesh device. Last week it failed to remove four cases from a consolidated multidistrict litigation suit in the U.S. District Court for Western Virginia.

Jazz Pharmaceuticals joins AstraZeneca and Lilly on Box's client list

Jazz Pharmaceuticals and Boston Scientific have begun using Box as their main platform for managing and collaborating on content.

Boston Sci to develop two new guidewires with cardiological indications by 2015

Boston Scientific has just announced plans to launch new fractional flow reserve and atherectomy guidewires in 2015 in collaboration with Japanese medical component specialist Asahi Intecc.

Boston Scientific down on disclosure of subpoena about Bridgepoint acquisition

A Securities and Exchange Commission filing from Aug. 6 disclosed that Boston Scientific received a subpoena from the U.S. Attorney for the District of New Jersey regarding its acquisition of Bridgepoint Medical, leading to a sharp decline in trading. 

Boston Scientific wins first vaginal mesh case to go to trial

Boston Scientific scored a victory in its ongoing transvaginal mesh saga, winning the first case to go to trial in Massachusetts state court.

Boston Scientific hopes to capitalize on competitors' weaknesses

Boston Scientific thinks it will benefit from recent less-than-favorable studies of competitor devices. The company is trotting out data for a bioresorbable stent from Abbott and transvenous leads in some St. Jude Medical products that highlight the advantages of its own offerings.

Renewed concerns about Riata leads create opportunity for Boston Scientific's S-ICD

On the heels of a recent Danish study highlighting the safety concerns plaguing St. Jude Medical's Riata defibrillator leader leads, Boston Scientific chief medical officer Ken Stein told  FierceMedicalDevices  he expects the company's subcutaneous implantable defibrillator, the S-ICD system, to eventually become the treatment of choice for heart patients because the device does not utilize transvenous leads that connect directly to the heart.      

Boston Scientific wins CE mark for 25-mm drug-eluting Lotus Transcatheter Aortic Valve

Boston Scientific's Ranger drug-coated balloon catheter was recently awarded a CE mark for its 25-mm Lotus Transcatheter Aortic Valve Implantation System.